Drug · DIN 02532476
SUNLENCA
SINGLE-DOSE VIALS
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 15, 2023; first marketed March 15, 2023.
- Drug Identification Number (DIN)
- 02532476
- Company (DIN owner)
- Gilead Sciences Canada IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Lenacapavir J05AX31
- Class
- Human
- Record last updated
- September 10, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LENACAPAVIR (LENACAPAVIR SODIUM) | 309 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 2, 2022: NOC 29368New Drug Submission (NDS)
Other DINs named SUNLENCA
- DIN 02532468 · Marketed